OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Related Content: